Epic Sciences is currently involved in over 60 active clinical trials that aim to evaluate CTCs in a number of different cancer indications. We also participate in research collaborations that allow us to better understand metastatic disease heterogeneity across multiple disease indications and therapeutic settings.
Epic Sciences works closely with biotech and pharmaceutical companies around the world as well as academic partners who are interested in integrating CTCs into clinical trials as observational or predictive biomarkers. It’s all about developing diagnostic assays that can empower precision medicine.
Epic Sciences’ proprietary CTC detection and characterization platform supports over 60 active clinical trials for 12 cancer indications.